Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,

#756 Evaluation of VEGF, VEGFR 1-2-3 and Endocan/ESM-1 Expression in Gastroenteropancreatic Neuroendocrine Tumors and Correlation with Ki-67 Labeling and Prognosis

Introduction: Angiogenesis is recognized to play a critical role in progressive tumor growth and spreading and its inhibition is a valuable approach to cancer treatment. Markers of angiogenesis include assessment of microvessel density on tissue sections (often evaluated with antibodies against pan-endothelial antigens, such as CD34) and expression of vascular endothelial growth factor (VEGF) and its receptors (VEGFR 1-2-3). Endocan, also called endothelial cell specific molecule-1 (ESM-1), has been shown to be expressed by endothelial tumor cells and especially by tip cells during angiogenesis. Endocan is highly up-regulated by pro-angiogenic molecules, such as VEGF. Recently, Endocan has been identified to be one of the molecules involved in the switch from dormant to fast-growing tumors. Among endocrine tumors, Endocan expression has been evaluated only in pituitary adenomas: a positive association between endothelial Endocan expression and recurrence risk, tumor size, tumoral invasion and average mitosis count has been demonstrated. In contrast, there was no association between endothelial Endocan expression and the Ki-67 labeling index

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Lugli F, Iacovazzo D, Fusco A, Lanza P, Rindi G,

Keywords: endocan, angiogenesis, vegf,